Injectable formulation, method for treating metabolic disease and administration device

Abstract

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

Dependencies are inferred from the claim text.